Denali Therapeutics Inc. Common Stock
Here’s whether Denali Therapeutics Inc. Common Stock (DNLI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 50 — healthy momentum range; strong 1-year return of +36.5%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.68% over 10 days); 3-month momentum negative (-13.0%). Currently 21.6% off its 52-week high. Score: +1/7.
DNLI is holding above its long-term 200-day MA ($17.83) but has slipped below the 50-day MA ($19.69), pointing to short-term weakness in an otherwise intact trend. An RSI of 49.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +36.5% compares to +27.9% for SPY (beat the market by 8.6%). The current 21.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.